Why Insurers Say No
Common Reasons Wegovy Is Denied
Denials Are Common—But Appealable
Only 19% of large employer health plans cover GLP-1 weight-loss medications like Wegovy. Even when coverage exists, prior authorization (pre-approval from your insurer) denial rates run as high as 62%. Understanding why helps you fight back.[1][4]
Insurance companies deny Wegovy coverage for several specific reasons. Each denial type has its own logic, requirements, and appeal strategy. Below, we break down each one—and link to detailed guides on how to respond.
Just got your denial? Start with our immediate next steps guide to understand what to do right now.
Each requires a different approach
Types of Insurance Denials
Medical Necessity
Insurer claims treatment isn't clinically required
Learn how to appeal →Step Therapy
Required to try cheaper medications first
Learn how to appeal →Formulary Exclusion
Wegovy not on your plan's drug list
Learn how to appeal →BMI Criteria
Doesn't meet BMI or health condition thresholds
Learn how to appeal →Lifestyle Documentation
Missing proof of diet/exercise attempts
Learn how to appeal →Other Common Reasons
- Body Mass Index (BMI) not documented or not recent
- No comorbidity (other health conditions like diabetes or high blood pressure) documentation
- Missing weight-management history
- No Medical Necessity Letter
- Incorrect diagnosis codes (ICD-10)
- Step therapy not addressed
- Insurer says Wegovy "excluded for obesity"
- Wrong PA form submitted
- Missing labs (A1C for diabetes, lipids for cholesterol, TSH for thyroid)
- Prior authorization incomplete
- PA never submitted by provider/pharmacy
Alternative Pathway: Cardiovascular (CV) Indication
If your plan excludes weight loss medications or you've been denied multiple times, there may be another option.
The SELECT trial showed Wegovy reduces major cardiovascular events (heart attacks, strokes, and cardiovascular death) by 20% in adults with established cardiovascular disease and either obesity or overweight.[5] This cardiovascular benefit may qualify you for coverage even when weight loss alone doesn't.
If you have a history of heart disease, heart attack, stroke, or peripheral artery disease, ask your doctor about appealing based on cardiovascular risk reduction rather than weight loss alone.
Alternative Pathway: MASH (Liver Disease) Indication
In August 2025, the FDA approved Wegovy for treating MASH (metabolic dysfunction-associated steatohepatitis)—a serious form of fatty liver disease affecting ~15 million Americans.[11]
In the ESSENCE trial, 63% of patients on Wegovy had MASH resolution vs 34% on placebo. If you have MASH with moderate to advanced fibrosis (stages F2-F3), this indication may provide an alternative coverage pathway—even on plans that exclude weight loss drugs.
Do you qualify? If you have elevated liver enzymes (ALT, AST) or fatty liver on imaging, ask your doctor about testing for MASH with a FibroScan.
Formulary Advantage: CVS Caremark Prefers Wegovy
As of July 2025, CVS Caremark moved Wegovy to preferred status on its largest commercial formularies, while removing Zepbound. Since October 1, 2026, Zepbound is back on CVS Caremark’s commercial template formularies as an additional preferred option (plan sponsors can customize).[8] If your PBM (pharmacy benefit manager) is CVS Caremark, you may have better coverage for Wegovy than other GLP-1s.
Can't wait for your appeal? Many patients use NovoCare savings programs to start treatment while their appeal processes—$199/mo intro pricing for new patients, then $349/mo self-pay—then switch to insurance once approved.
Step-by-step appeal process
How to Respond to a Wegovy Denial
Below is the exact process that leads to successful appeals.
You can complete it manually — or Honest Care can guide you through each step.
1Review Your Denial Letter
Review Your Denial Letter
Upload your denial letter and we help you make sense of it — pinpointing the most likely reason for your denial and what that means for next steps.
2Answer Quick Assessment Questions
Answer Quick Assessment Questions
We ask a few targeted questions to understand your situation, insurance setup, and medical history.
Normally, you would:
- Try to guess which denial category applies
- Look up your insurer's specific rules
- Try to decode terminology like "insufficient documentation" or "step therapy required"
- Figure out what information actually matters
With Honest Care:
- Our assessment asks the right questions up front
- Your answers help us identify your denial category quickly
- We map your situation to patterns we've seen in real Wegovy denials
- You get a clearer sense of what direction your appeal needs to go
3Gather Your Required Documentation
Gather Your Required Documentation
We help you understand which documents matter for your specific denial type — and which don't.
Normally, you would:
- Guess what documentation is required
- Over-collect or under-collect information
- Miss key items like ICD-10 codes, lifestyle notes, or prior med trials
- Possibly submit incomplete evidence
With Honest Care:
- We show you which documents are usually needed for your specific denial
- We help you avoid unnecessary paperwork
- We connect your documentation needs to your insurer's expectations
- Everything becomes clearer and more organized
4Honest Care Crafts Your Appeal Letter
Honest Care Crafts Your Appeal Letter
Based on your denial, assessment answers, and documentation, our team writes your appeal letter.
Normally, you would:
- Search online for templates
- Try to write your own appeal from scratch
- Not know how insurers evaluate clinical arguments
- Struggle to connect documentation to the denial reason
With Honest Care:
- Our team writes your personalized appeal letter
- It directly addresses your specific denial reason
- We incorporate your history, documentation, and insurer expectations
- You get an insurer-ready letter that's structured correctly and professionally worded
5Submit Your Appeal
Submit Your Appeal
We help you assemble and submit your complete appeal packet through your insurer's portal, fax, or mail.
Normally, you would:
- Try to figure out which documents go where and in what order
- Not know which forms to include or how to structure your packet
- Look up the correct submission channel (portal, fax, mail)
- Worry about technicalities like reference numbers or attachments
With Honest Care:
- We help you put everything in the correct order with all required documentation
- Provide instructions based on your insurer's submission method
- Guide you toward the correct submission route
- Help ensure you don't miss key pieces like reference numbers, signatures, or attachments
How to Build a Strong Case
Appeal Strategies That Work
Strategy 1 — Strengthen Your Medical Necessity Letter
Your doctor's letter should include:
- Why Wegovy is medically necessary
- Detailed comorbidity risks (type 2 diabetes, high blood pressure, heart disease, sleep apnea)
- Why untreated obesity is dangerous for you
- Past lifestyle attempts (diet programs, exercise regimens)
- Prior medication failures or intolerance
- Clinical evidence supporting Wegovy (STEP trials, SELECT trial)
Strategy 2 — Fix Documentation Gaps
Check whether your denial cites missing documentation.
Checklist:
- Recent BMI (30–90 days)
- Other health condition diagnosis codes
- Lifestyle modification timeline
- Lab results (diabetes test, cholesterol, thyroid)
- Prior medication trials
- Treatment & follow-up notes
Strategy 3 — Address Step Therapy Head-On
Provide:
- Why cheaper alternatives won't work
- Side effects or intolerance to prior medications
- Contraindications (reasons you can't take certain drugs)
- Failure of past treatments
Strategy 4 — Engage Employers When Plans Exclude GLP-1s
If the plan excludes Wegovy:
- Appeal using medical framing (focus on health conditions, not weight)
- Request a benefit exception
- Provide comorbidity documentation
- Ask HR about mid-year accommodation
Strategy 5 — Leverage Cardiovascular Benefit Evidence
Wegovy has unique advantages over other GLP-1s:
- SELECT trial: 20% reduction in heart attacks, strokes, and cardiovascular death[5]
- If you have established cardiovascular disease, frame your appeal around cardiovascular protection
- This positions Wegovy as a heart medication, not just a weight loss drug
- Some insurers have different coverage criteria for cardiovascular indications
Quick Reference Table
Common Denial Reasons & How to Fix Them
| Denial Reason | What It Means | How to Fix |
|---|---|---|
| BMI not documented | Missing height/weight | Submit updated BMI + chart note |
| No lifestyle documentation | Insurer needs proof | Provide 3–12 month diet/exercise timeline |
| Step therapy required | Must try alternatives first | Document failure, intolerance, or contraindication |
| "Not medically necessary" | Insurer disputes need | Strengthen Medical Necessity Letter |
| Drug excluded | Plan excludes GLP-1s | File benefit exception + speak to HR |
| PA not on file | PA never submitted | Ask provider/pharmacy to resubmit |
| Incorrect codes | Missing ICD-10 | Add obesity + comorbidities codes |
What to Expect
Appeal Success Rates & Timelines
Timelines
- Internal appeal: 30–60 days
- External review: 45 days (72 hours if urgent)
- Urgent appeal: 72 hours
- Internal appeal deadline: 180 days
- External review deadline: 4 months after the final internal denial (some states allow longer)
They worked with me regardless of my backwards approach
I really appreciate everything that Honest Care has done to help me prepare my appeal to my insurance for medication. The professional letter and the supporting document that were compiled on my behal...
Helped me in the 11th hour
I am so grateful for Honest Care's services. They helped me out in the 11th hour. After doing hours of online research and written 5 or more drafts of an appeal letter, I felt deflated and exhausted t...
Worth every penny
When I received my denial letter from my insurance I was devastated and started searching how to write an appeal letter. I came across Honest Care in a group chat and I'm so happy I did. After answeri...
Your GLP-1 coverage,
denied approved
✓ Free Templates✓ Premium Support Available
I was denied coverage for...
Get startedWHAT'S CHANGING
Wegovy Appeals: 2026 Outlook
2026: Prior Authorization Reform Takes Effect
The CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F) took effect January 1, 2026: From January 1, 2026, Medicare Advantage, Medicaid and CHIP must decide medical prior authorizations within 7 days (72 hours if urgent); the rule excludes drugs. Because it excludes drugs, it doesn't change Wegovy prior authorization timelines; for most employer and ACA plans, the federal limit is within 15 days (72 hours if urgent).[6]
State-Level PA Reform Gains Momentum
Several states are implementing stronger prior authorization protections in 2026:
- California SB 1120: Requires physician review of denials (not just algorithms)
- Texas: New "gold carding" program exempts providers with 90%+ approval rates from PA
- Michigan, Illinois, Ohio: Pending legislation to limit step therapy requirements
Check your state's insurance department for specific 2026 changes that may affect your appeal rights.
If Your Appeal Fails: NovoCare Self-Pay Options
If appeals don't succeed, NovoCare offers Wegovy at reduced cash prices:
- New patients: $199/month for the first two fills (0.25 mg and 0.5 mg), through December 31, 2026
- All patients: $349/month ($399 for Wegovy HD 7.2 mg) after intro period
- Oral Wegovy (NEW): $149–$299/month by dose (approved December 22, 2025)
These options require a prescription and do not use insurance. Visit novocare.com for current pricing.
Medicare Part D: Cardiovascular Indication Pathway
By law, basic Medicare Part D coverage excludes drugs used for weight loss (some enhanced plans could offer them as supplemental benefits), but Wegovy's proven cardiovascular benefits (20% MACE reduction in SELECT trial) create a coverage pathway for Medicare patients.
The FDA approved Wegovy's cardiovascular indication for adults with established cardiovascular disease and either obesity or overweight (injection: March 8, 2024 (Wegovy injection); tablets: December 22, 2025 (Wegovy tablets)), so for those patients Wegovy may be covered under Part D—regardless of the weight loss exclusion—subject to the plan’s formulary, prior authorization and exceptions process. For weight loss itself, the Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027), which runs outside the Part D benefit, covers Wegovy for $50 per monthly fill if you meet CMS’s criteria and your prescriber gets prior authorization.
If you're on Medicare and have heart disease, ask your doctor about documenting your cardiovascular disease for a Part D prior authorization.
Oral Wegovy: New Option in 2026
The FDA approved oral Wegovy (semaglutide 25mg pill) on December 22, 2025, with pharmacy availability starting January 5, 2026.
- Same active ingredient: Semaglutide (same as injectable Wegovy)
- Lower price: $149–$299/month self-pay vs $349/month for the injectable (list price $1,349/month)
- Daily dosing: Once-daily pill vs weekly injection
- Weight loss: 13.6-16.6% in OASIS trials[9]
If you're appealing for injectable Wegovy and struggling with coverage, the oral version may offer a more affordable alternative—and some insurers may have different coverage criteria for the pill form.
Employer Plan Changes
Open enrollment for 2026 plans runs from November 2025 through January 2026 for most employers. Key trends:
- More employers adding GLP-1 coverage: Rising from 19% to an estimated 25%+ of large employers
- New weight management programs: Some employers requiring enrollment in lifestyle programs to qualify
- Stricter PA requirements: Many plans implementing BMI thresholds and step therapy
If your current plan excludes Wegovy, check if your 2026 plan options offer better coverage during open enrollment.
Appeals & Denials FAQs
Frequently Asked Questions
No. Most appeals are handled by you + your provider. Legal representation is not required for insurance appeals.
Yes — and it's completely free. We write personalized letters based on your insurer and denial.
You may still qualify via:
- Benefit exception
- External review
- Employer-level request
Yes, and many do — but we recommend reviewing the letter first to ensure it addresses the specific denial reason.
Yes, if you pay cash. NovoCare offers $199/month for the first two fills (0.25 mg and 0.5 mg), through December 31, 2026, then $349/month ($399 for Wegovy HD 7.2 mg). Or try the new oral Wegovy at $149–$299/month. This lets you start treatment while your appeal processes.
You likely lose the right to appeal that denial. Act quickly. The 180-day clock starts from the date on your denial letter.
Standard appeals: 30–60 days. Urgent appeals (if medically necessary): 72 hours. Insurers must notify you of their decision within these timeframes.
An independent third-party review of your case if your internal appeal is denied. External reviewers are not employed by your insurer and often have higher success rates than internal appeals. About 50% of external reviews are overturned.
Key documents include: your denial letter, BMI history (ideally showing BMI ≥30 or ≥27 with comorbidities), documentation of weight-related conditions (type 2 diabetes, hypertension, sleep apnea, heart disease), records of prior weight loss attempts (diet programs, other medications), recent lab work, and a Letter of Medical Necessity from your provider.
A formal letter from your doctor explaining why Wegovy is medically necessary for your specific situation. It should include your diagnosis, BMI history, failed alternative treatments, and why Wegovy is the appropriate choice. This letter is often the most important document in your appeal.
A phone call between your prescribing doctor and the insurance company's medical director to discuss your case. Per AMA guidelines, these calls typically last 5–10 minutes and should be scheduled within 24–72 hours of request. They can be highly effective — come prepared with specific clinical details.
You have options: (1) File another internal appeal if your plan allows multiple levels, (2) Request an external review — an independent third party reviews your case, (3) File a complaint with your state insurance commissioner. Under federal law (45 CFR § 147.136), you have the right to external review after exhausting internal appeals.
Success rates vary by appeal type. Internal appeals succeed approximately 44% of the time. Prior authorization appeals are overturned in about 80% of cases when pursued (AMA/KFF 2023). The challenge? Fewer than 1% of denied claims are ever appealed, meaning most people give up too soon.
The Wegovy Savings Offer requires commercial insurance coverage to activate the full discount ($0-$25/month). If you're paying cash while appealing, use NovoCare self-pay pricing: $199/month for the first two fills (0.25 mg and 0.5 mg), through December 31, 2026, or $349/month ($399 for Wegovy HD 7.2 mg) regular. The new oral Wegovy is $149–$299/month. See our Wegovy cost guide for all options.
Most plans offer 2–3 levels: (1) Internal appeal to your insurer, (2) Second-level internal appeal (some plans), (3) External review by an independent organization. Under ERISA (29 CFR 2560.503-1) and ACA regulations, you're entitled to at least one internal appeal and one external review for non-grandfathered plans.
Appeals Deep Dives
Learn more about specific aspects of the appeal process:
- How Honest Care Helps — Our evidence-backed appeal letter service
References
- Department of Labor. "Claims Procedure." ERISA Section 503. 29 CFR 2560.503-1. Accessed January 2026. https://www.dol.gov/agencies/ebsa
- Centers for Medicare & Medicaid Services. "Internal Claims and Appeals and External Review Processes." 45 CFR 147.136. Federal Register, 2015. https://www.federalregister.gov
- American Medical Association. (2023). "Over 80% of Prior Auth Appeals Succeed—Why Aren't There More?" ama-assn.org
- National Association of Insurance Commissioners (NAIC). "Consumer Health Insurance Complaints by Coverage Type." NAIC Report, 2024. https://content.naic.org
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." New England Journal of Medicine. 2023;389(24):2221-2232. NEJM - SELECT Trial
- Centers for Medicare & Medicaid Services. "CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F)." January 2024. https://www.cms.gov
- National Conference of State Legislatures (NCSL). "External Review of Health Insurance Claims." State Health Insurance Mandates, 2024. https://www.ncsl.org
- CVS Caremark. "Formulary Updates: GLP-1 Weight Management Medications." Effective July 1, 2025. caremark.com
- U.S. Food and Drug Administration. "FDA Approves Oral Semaglutide for Weight Management." FDA News Release, December 22, 2025. fda.gov
- Novo Nordisk. "NovoCare Savings Programs for Wegovy." NovoCare, 2025. novocare.com
- U.S. Food and Drug Administration. "FDA Approves Treatment for Serious Liver Disease Known as 'MASH'." FDA News Release, August 15, 2025. fda.gov
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.